Tags: Clinical trials

Pfizer Announces IBRANCE Clinical Trials Ended Early In Light of Promising News

In light of promising results conducted by an independent data monitoring committee, Pfizer’s newest treatment IBRANCE (Palbociclib) ended clinical trials early this week as phase 3 of the trials ended demonstrating improvement in progression-free survival in women who had undergone treatment for metastatic breast cancer.
1

Recommended Stories

Real Time Analytics